Bronchiolitis obliterans syndrome/obliterative bronchiolitis ameliorated by azithromycin

genotype had apr (p 0.024). for the il-10 haplotype gcc/acc versus gcc/ata, which were the genotypes associated with int il-10 production, gcc/acc had 31 out of 43 patients (72%) with apr in comparison with gcc/ata in which there were 10 out of 22 patients (45%) with apr (p 0.035). Conclusion: In LT patients, the IL-10 high genotype is protective against APR in comparison to int/low IL-10 genotypes. The IL-10 intermediate genotype in LT patients can be differentiated into two haplotype responses with the GCC/ACC having more APR. The homozygous high IL-10 genotype may be protective against lung rejection by reducing inflammatory cytokines and downregulating APCs. Future pharmacogenomic models may incorporate these associations with APR in LT patients to formulate individualized therapeutic regimens.